The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 1, 2013, Pages 57-67

  Motiwala, S R ^a   Januzzi, J L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NATRIURETIC FACTOR;

ADVERSE OUTCOME; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMEGALY; CLEARANCE; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DISEASE CONTROL; DIURESIS; DRUG EFFECT; EXERCISE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE VOLUME; HEART TAMPONADE; HEART VOLUME; HOSPITAL DISCHARGE; HUMAN; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; PROTEIN SECRETION; PULMONARY HYPERTENSION; PULMONARY VALVE STENOSIS; SYSTOLIC DYSFUNCTION; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; CHRONIC DISEASE; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; MOLECULAR SEQUENCE DATA; NATRIURETIC PEPTIDES; PRACTICE GUIDELINES AS TOPIC;

EID: 84871336360     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.187     Document Type: Article

References (75)

1. Hunt, S.A. et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53, e1-e90 (2009).
2. Fonarow, G.C. et al. Improving evidence-based care for heart failure in outpatient cardiology practices: Primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 122, 585-596 (2010).
3. Gheorghiade, M. et al. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: Findings from IMPROVE HF. Congest. Heart Fail. 18, 9-17 (2012).
4. van Kimmenade, R.R. & Januzzi, J.L. Jr. Emerging biomarkers in heart failure. Clin. Chem. 58, 127-138 (2012).
5. de Bold, A.J., Borenstein, H.B., Veress, A.T. & Sonnenberg, H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28, 89-94 (1981).
6. Sudoh, T., Kangawa, K., Minamino, N. & Matsuo, H. A new natriuretic peptide in porcine brain. Nature 332, 78-81 (1988).
7. Tamura, N., Ogawa, Y., Yasoda, A., Itoh, H., Saito, Y. & Nakao, K. Two cardiac natriuretic peptide genes (atrial natriuretic peptide and brain natriuretic peptide) are organized in tandem in the mouse and human genomes. J. Mol. Cell. Cardiol. 28, 1811-1815 (1996).
8. Suga, S. et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 130, 229-239 (1992).
9. Lam, C.S., Burnett, J.C. Jr, Costello-Boerrigter, L., Rodeheffer, R.J. & Redfield, M.M. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J. Am. Coll. Cardiol. 49, 1193-1202 (2007).
10. Charles, C.J. et al. Clearance receptors and endopeptidase 24.11: Equal role in natriuretic peptide metabolism in conscious sheep. Am. J. Physiol. 271, R373-R380 (1996).
11. van Kimmenade, R.R. et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J. Am. Coll. Cardiol. 53, 884-890 (2009).
12. Deschodt-Lanckman, M., Michaux, F., De Prez, E., Abramowicz, D., Vanherweghem, J.L. & Goldman, M. Increased serum levels of endopeptidase 24.11 ('enkephalinase') in patients with end-stage renal failure. Life Sci. 45, 133-141 (1989).
13. Andreassi, M.G., Del Ry, S., Palmieri, C., Clerico, A., Biagini, A. & Giannessi, D. Up-regulation of 'clearance' receptors in patients with chronic heart failure: A possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur. J. Heart Fail. 3, 407-414 (2001).
14. Mäntymaa, P., Vuolteenaho, O., Marttila, M. & Ruskoaho, H. Atrial stretch induces rapid increase in brain natriuretic peptide but not in atrial natriuretic peptide gene expression in vitro. Endocrinology 133, 1470-1473 (1993).
15. Magga, J., Vuolteenaho, O., Tokola, H., Marttila, M. & Ruskoaho, H. Involvement of transcriptional and posttranscriptional mechanisms in cardiac overloadinduced increase of B-type natriuretic peptide gene expression. Circ. Res. 81, 694-702 (1997).
16. Bruneau, B.G., Piazza, L.A. & de Bold, A.J. BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am. J. Physiol. 273, H2678-H2686 (1997).
17. Magga, J., Vuolteenaho, O., Marttila, M. & Ruskoaho, H. Endothelin-1 is involved in stretch-induced early activation of B-type natriuretic peptide gene expression in atrial but not in ventricular myocytes: Acute effects of mixed ET(A)/ET(B) and AT1 receptor antagonists in vivo and in vitro. Circulation 96, 3053-3062 (1997).
18. Goetze, J.P., Gore, A., Møller, C.H., Steinbrüchel, D.A., Rehfeld, J.F. & Nielsen, L.B. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 18, 1928-1930 (2004).
19. Möllmann, H. et al. Ischemia triggers BNP expression in the human myocardium independent from mechanical stress. Int. J. Cardiol. 143, 289-297 (2010).
20. Casals, G., Ros, J., Sionis, A., Davidson, M.M., Morales-Ruiz, M. & Jiménez, W. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 297, H550-H555 (2009).
21. Weidemann, A. et al. Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem. J. 409, 233-242 (2008).
22. Khan, A.M. et al. Cardiac natriuretic peptides, obesity, and insulin resistance: Evidence from two community-based studies. J. Clin. Endocrinol. Metab. 96, 3242-3249 (2011).
23. Schultz, M. et al. N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin. Endocrinol. (Oxf) 60, 54-59 (2004).
24. Chen, A.A. et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: Results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur. Heart J. 27, 839-845 (2006).
25. Khan, I.A., Fink, J., Nass, C., Chen, H., Christenson, R. & deFilippi, C.R. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am. J. Cardiol. 97, 1530-1534 (2006).
26. Kim, H.N. & Januzzi, J.L. Jr. Natriuretic peptide testing in heart failure. Circulation 123, 2015-2019 (2011).
27. Scott, P.A. et al. Defining potential to benefit from implantable cardioverter defibrillator therapy: The role of biomarkers. Europace 13, 1419-1427 (2011).
28. Latini, R. et al.; Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am. J. Med. 119, 70 e23-70.e30 (2006).
29. McIntyre, H.F. Leveraging guidelines: Understanding heart failure, organizing care. Commentary on the 2010 NICE chronic heart failure guideline update. Eur. J. Heart Fail. 13, 14-17 (2011).
30. Masson, S. et al.; Val-HeFT Investigators. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin. Chem. 52, 1528-1538 (2006).
31. Masson, S. et al.; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J. Am. Coll. Cardiol. 52, 997-1003 (2008).
32. Araújo, J.P., Azevedo, A., Lourenço, P., Rocha-Gonçalves, F., Ferreira, A. & Bettencourt, P. Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am. J. Cardiol. 98, 1248-1250 (2006).
33. Schou, M., Gustafsson, F., Nielsen, P.H., Madsen, L.H., Kjaer, A. & Hildebrandt, P.R. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur. J. Heart Fail. 9, 68-74 (2007).
34. Pascual-Figal, D.A. et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur. Heart J. 29, 1011-1018 (2008).
35. Cioffi, G. et al. Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function. J. Card. Fail. 12, 608-615 (2006).
36. Tsutamoto, T. et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37, 1228-1233 (2001).
37. Berry, C. et al. Effects of aldosterone receptor blockade in patients with mildmoderate heart failure taking a beta-blocker. Eur. J. Heart Fail. 9, 429-434 (2007).
38. Kohno, M. et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left venticular hypertrophy. Metab. Clin. Exp. 49, 1356-1360 (2000).
39. White, M., Rouleau, J.L., Afzal, R., Floras, J., Yusuf, S. & McKelvie, R.S. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. Ther. Adv. Cardiovasc. Dis. 3, 113-121 (2009).
40. Anand, I.S. et al.; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107, 1278-1283 (2003).
41. Richards, A.M. et al.; Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J. Am. Coll. Cardiol. 37, 1781-1787 (2001).
42. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : The randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 101, 378-384 (2000).
43. Hartmann, F. et al. NT-proBNP in severe chronic heart failure: Rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur. J. Heart Fail. 6, 343-350 (2004).
44. Conraads, V.M. et al. Combined endurance/resistance training reduces NTproBNP levels in patients with chronic heart failure. Eur. Heart J. 25, 1797-1805 (2004).
45. Passino, C. et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J. Am. Coll. Cardiol. 47, 1835-1839 (2006).
46. Fruhwald, F.M. et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur. Heart J. 28, 1592-1597 (2007).
47. Braunschweig, F. et al. Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur. J. Heart Fail. 8, 797-803 (2006).
48. Y oshida, Y. et al. Aldosterone signaling associates with p300/GATA4 transcriptional pathway during the hypertrophic response of cardiomyocytes. Circ. J. 74, 156-162 (2010).
49. Oda, T., Iijima, Y., Sada, T., Nishino, H., Oizumi, K. & Koike, H. Effects of chronic treatment with a novel angiotensin converting enzyme inhibitor, CS622, and a vasodilator, hydralazine, on atrial natriuretic factor (ANF) in spontaneously hypertensive rats (SHR). Biochem. Biophys. Res. Commun. 152, 456-462 (1988).
50. Y oshimoto, T. et al. Angiotensin converting enzyme inhibitor but not calcium blocker down-regulates gene expression of vascular natriuretic peptide receptor in hypertensive rats. Biochem. Biophys. Res. Commun. 205, 1595-1600 (1994).
51. Fukui, K. et al. Captopril and hydralazine suppress atrial natriuretic peptide (ANP) gene expression in the ventricles of spontaneously hypertensive rat. Biochem. Biophys. Res. Commun. 160, 310-316 (1989).
52. Davis, M.E., Richards, A.M., Nicholls, M.G., Yandle, T.G., Frampton, C.M. & Troughton, R.W. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113, 977-985 (2006).
53. Sanderson, J.E. et al. Beta blockers in heart failure: A comparison of a vasodilating beta blocker with metoprolol. Heart 79, 86-92 (1998).
54. Frantz, R.P. et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am. Heart J. 149, 541-547 (2005).
55. Liao, Y. et al. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overloadinduced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110, 692-699 (2004).
56. Troughton, R.W., Frampton, C.M., Yandle, T.G., Espiner, E.A., Nicholls, M.G. & Richards, A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130 (2000).
57. Berger, R. et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J. Am. Coll. Cardiol. 55, 645-653 (2010).
58. Jourdain, P. et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49, 1733-1739 (2007).
59. Januzzi, J.L. Jr et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 58, 1881-1889 (2011).
60. Lainchbury, J.G. et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NTproBNP- Assisted Treatment To Lessen Serial Cardiac Readmissions and Death trial. J. Am. Coll. Cardiol. 55, 53-60 (2009).
61. Pfisterer, M. et al.; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301, 383-392 (2009).
62. Eurlings, L.W. et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: Results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J. Am. Coll. Cardiol. 56, 2090-2100 (2010).
63. Persson, H., Erntell, H., Eriksson, B., Johansson, G., Swedberg, K. & Dahlström, U. Improved pharmacological therapy of chronic heart failure in primary care: A randomized Study of NT-proBNP Guided Management of Heart Failure-SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur. J. Heart Fail. 12, 1300-1308 (2010).
64. Shah, M.R. et al. The STARBRITE trial: A randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J. Card. Fail. 17, 613-621 (2011).
65. Karlström, P., Alehagen, U., Boman, K. & Dahlström, U.; UPSTEP-study group. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: Responders to treatment have a significantly better outcome. Eur. J. Heart Fail. 13, 1096-1103 (2011).
66. Felker, G.M., Hasselblad, V., Hernandez, A.F. & O'Connor, C.M. Biomarkerguided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. Am. Heart J. 158, 422-430 (2009).
67. Porapakkham, P., Porapakkham, P., Zimmet, H., Billah, B. & Krum, H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch. Intern. Med. 170, 507-514 (2010).
68. Januzzi, J.L. Jr. Use of biomarkers to "guide" care in chronic heart failure: What have we learned (so far)? J. Card. Fail. 17, 622-625 (2011).
69. Bhardwaj, A., Rehman, S.U., Mohammed, A., Baggish, A.L., Moore, S.A. & Januzzi, J.L. Jr. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am. Heart J. 159, 532-538.e1 (2010).
70. Cavallari, L.H. & Limdi, N.A. Warfarin pharmacogenomics. Curr. Opin. Mol. Ther. 11, 243-251 (2009).
71. Michtalik, H.J. et al. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am. J. Cardiol. 107, 1191-1195 (2011).
72. Kociol, R.D. et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: Data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ. Heart Fail. 4, 628-636 (2011).
73. Bettencourt, P., Azevedo, A., Pimenta, J., Friões, F., Ferreira, S. & Ferreira, A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110, 2168-2174 (2004).
74. Wang, T.J. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350, 655-663 (2004).
75. McKie, P.M. et al. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J. Am. Coll. Cardiol. 55, 2140-2147 (2010).